<DOC>
	<DOC>NCT02295150</DOC>
	<brief_summary>This study is a prospective evaluation of the relationship between lean body weight and anti-Xa activity and 5700 International Units (IU) nadroparin 4 hours after subcutaneous administration in morbidly obese patients after bariatric surgery.</brief_summary>
	<brief_title>Prophylaxis of Venous Thromboembolism After Bariatric Surgery</brief_title>
	<detailed_description>There is no guideline for postoperative thromboembolic prevention in morbidly obese patients. The investigators goal is to examine which dose of nadroparin is effective.</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Obesity, Morbid</mesh_term>
	<mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Nadroparin</mesh_term>
	<criteria>Approval for RouxenY gastric bypass Total body weight &gt; 140 kg Renal impairment (GFR &lt; 30ml/min and/ or serum creatinin &gt; 150 micromol/ml) Coagulation disorders Use of vitamin K antagonists (such as acenocoumarol) pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Nadroparin</keyword>
	<keyword>Anti-Xa activity</keyword>
</DOC>